OncoMatch/Clinical Trials/NCT07297173
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Is NCT07297173 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HLA-mismatched GPBMC infusion for relapsed leukemia.
Treatment: HLA-mismatched GPBMC infusion — This is a Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of chemotherapy combining with HLA-mismatched G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion as a bridging therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed and refractory (R/R) leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Lab requirements
Kidney function
serum creatinine <= 2 × ULN or CrCl >= 40 mL/min
Liver function
ALT and AST <= 3 × ULN, total bilirubin <= 1.5 × ULN
Cardiac function
LVEF > 50% by echocardiogram; no significant cardiovascular disease (uncontrolled/highly symptomatic arrhythmias, CHF, MI within 6 months, NYHA class 3 or 4)
Adequate hepatic function including alanine transaminase (ALT) and aspartate aminotransferase (AST )<= 3 × upper limit of normal(ULN), and total bilirubin <= 1.5 × ULN. Adequate renal function including serum creatinine <= 2 × ULN or CrCl>= 40mL/min. LVEF measured by echocardiogram is within the normal range (LVEF > 50%). Cardiovascular disease with clinical significance, such as uncontrolled or highly symptomatic cardiac arrhythmias, congestive heart failure, or myocardial infarction within 6 months prior to screening, or New York Heart Association (NYHA) function class 3 (moderate) or class 4 (severe) heart disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify